Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> alpha-Bisabolol [515-69-5]

alpha-Bisabolol [515-69-5]

Stampa Stampa
Entra

Cat# HY-121222-5g

Size : 5g

Marca : MedChemExpress


Description

alpha-Bisabolol, an orally active sesquiterpene alcohol, induces cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. alpha-Bisabolol exerts a protective action against Cisplatin (HY-17394)-induced nephrotoxicity by mitigating inflammation and oxidative stress through the inhibition of NFκB activation. alpha-Bisabolol exhibits anti-inflammatory, analgesic, antibiotic and anticancer activities[1][2].

IC50 & Target[1]

PI3K

 

In Vitro

alpha-Bisabolol (3.2-120 µM; 24 h) exerts antiproliferative effects on A549 cells[1].
alpha-Bisabolol (7.5-30 µM; 24 h) caused apoptosis in A549 cells in a concentration-dependent manner[1].
alpha-Bisabolol (7.5-30 µM; 24 h) induces G2/M cell cycle arrest of A549 cells[1].
alpha-Bisabolol (15 µM; 24 h) reduces the motility and migration of the of A549 cells in a dose-dependent manner[1].
alpha-Bisabolol (15 µM; 24 h) exhibits a dose-dependent downregulation of p-PI3K and p-AKT proteins[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

alpha-Bisabolol Related Antibodies

Cell Viability Assay[1]

Cell Line: A549 NSCLC cell line
Concentration: 3.2, 7.5, 15, 30, 60, 120 µM
Incubation Time: 24 h
Result: Displayed significant anticancer effects against A549 cells with an observed IC50 15 µM.

Apoptosis Analysis[1]

Cell Line: A549 NSCLC cell line
Concentration: 7.5, 15, 30 µM
Incubation Time: 24 h
Result: The percentage of apoptotic cells increased from 2.15% in the control to 48.5% at 30 µM concentration.

Cell Cycle Analysis[1]

Cell Line: A549 NSCLC cell line
Concentration: 7.5, 15, 30 µM
Incubation Time: 24 h
Result: The number of cells at G2 phase increased in a dose-dependent manner causing cell cycle arrest.

Cell Migration Assay [1]

Cell Line: A549 NSCLC cell line
Concentration: 15 µM
Incubation Time: 24 h
Result: Reduced the motility and migration of the of A549 cells in a dose-dependent manner.

Western Blot Analysis[1]

Cell Line: A549 NSCLC cell line
Concentration: 15 µM
Incubation Time: 24 h
Result: Exhibited a dose-dependent downregulation of p-PI3K and p-AKT proteins.
In Vivo

reduces the Cisplatin (HY-17394)-induced renal DNA damage, and markedly lessened the acute tubular necrosis observed in kidney histology[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male and female BALB/c mice weighing 25-30 g[1]
Dosage: 25 mg/kg
Administration: Orally; daily; for 7 days; continued for 3 more days
Result: Had significantly normalized the alterations of water intake, urine volume, relative kidney weight, and the concentrations of urea and creatinine, as well as the creatinine clearance induced by Cisplatin (CP; 20 mg/kg; ip; On day 7).
Significantly reduced the CP-induced renal DNA damage, and markedly lessened the acute tubular necrosis observed in kidney histology.
Masse moléculaire

222.37

Formule

C15H26O
CAS No.
Appearance

Liquid (Density: 0.93 g/cm3)

Color

Colorless to light yellow

SMILES

C/C(C)=C\CC[C@@](O)([C@@H]1CCC(C)=CC1)C
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (449.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.4970 mL 22.4850 mL 44.9701 mL
5 mM 0.8994 mL 4.4970 mL 8.9940 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (11.24 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (11.24 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références